CRMD vs. MRUS, ACAD, ACLX, SWTX, RARE, PTGX, SRRK, ALVO, MTSR, and CPRX
Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Scholar Rock (SRRK), Alvotech (ALVO), Metsera (MTSR), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.
CorMedix vs. Its Competitors
Merus (NASDAQ:MRUS) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking.
96.1% of Merus shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 4.6% of Merus shares are owned by insiders. Comparatively, 5.3% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
CorMedix has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
In the previous week, Merus had 2 more articles in the media than CorMedix. MarketBeat recorded 5 mentions for Merus and 3 mentions for CorMedix. CorMedix's average media sentiment score of 0.72 beat Merus' score of 0.70 indicating that CorMedix is being referred to more favorably in the news media.
Merus has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.
Merus currently has a consensus target price of $85.83, indicating a potential upside of 54.96%. CorMedix has a consensus target price of $15.00, indicating a potential upside of 0.94%. Given Merus' higher probable upside, equities research analysts plainly believe Merus is more favorable than CorMedix.
Merus received 332 more outperform votes than CorMedix when rated by MarketBeat users. However, 79.55% of users gave CorMedix an outperform vote while only 67.96% of users gave Merus an outperform vote.
CorMedix has a net margin of 0.00% compared to Merus' net margin of -680.61%. Merus' return on equity of -38.89% beat CorMedix's return on equity.
Summary
Merus beats CorMedix on 10 of the 19 factors compared between the two stocks.
Get CorMedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CorMedix Competitors List
Related Companies and Tools
This page (NASDAQ:CRMD) was last updated on 6/13/2025 by MarketBeat.com Staff
